Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2031 - Leading Companies are AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd.

Global Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2031 growing with a CAGR of 2.5% during the forecast period 2024-2031.

Homozygous Familial Hypercholesterolemia Market is thoroughly examined in the DataM Intelligence study, offering a comprehensive analysis supported by robust statistics, historical data, and actionable insights. The report evaluates key industry players, analyzing their product portfolios, pricing strategies, financial performance, and expansion efforts. It provides a clear understanding of market dynamics, competitive positioning, and anticipated trends shaping the future of the industry.

Get a Premium Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/homozygous-familial-hypercholesterolemia-market?rk

Rising Cardiovascular Disease Burden to Propel Homozygous Familial Hypercholesterolemia (HoFH) Market Growth
The increasing prevalence of cardiovascular diseases (CVDs) is a key factor driving the growth of the homozygous familial hypercholesterolemia (HoFH) market. HoFH is marked by extremely high LDL-C levels and significantly elevated risks of cardiovascular complications such as heart attacks and strokes. As awareness of the condition improves, early diagnosis and proactive treatment are gaining traction, boosting demand for effective HoFH therapies.

For example, the Centers for Disease Control and Prevention (CDC) reported in 2023 that heart disease remains one of the leading causes of death in the United States. Every 40 seconds, someone in the U.S. experiences a heart attack, totaling approximately 805,000 incidents annually. Coronary heart disease alone was responsible for 375,476 deaths in 2021. As cardiovascular health concerns continue to rise, the need for targeted HoFH treatments is expected to grow correspondingly over the forecast period.

List of the Key Players in the Homozygous Familial Hypercholesterolemia Market:

AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma.

Homozygous Familial Hypercholesterolemia Industry Development:

Evkeeza Receives FDA Approval Expansion for Pediatric HoFH Patients

On March 22, 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA has expanded the indication for Evkeeza (evinacumab-dgnb) to include children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering therapies. Evkeeza is now the first approved angiopoietin-like 3 (ANGPTL3) inhibitor for use in this young age group, offering a vital treatment option to help lower dangerously high LDL-C levels associated with HoFH.

Research Methodology

Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/homozygous-familial-hypercholesterolemia-market

Segment Covered in the Homozygous Familial Hypercholesterolemia Market:

By Drug Class: Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors.

By Route of Administration: Oral, Parenteral, Nasal.

By Technology: CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies.

By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Regional Analysis for Homozygous Familial Hypercholesterolemia Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Homozygous Familial Hypercholesterolemia market?

➠ Who are the global key manufacturers of the Homozygous Familial Hypercholesterolemia Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Homozygous Familial Hypercholesterolemia market opportunities and threats faced by the vendors in the global Homozygous Familial Hypercholesterolemia Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Homozygous Familial Hypercholesterolemia market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.